Kerbside

Kerbside

The recommendations provided in this column are taken from various market sources such as brokers, analysts, dealers and investment strategists, etc. These recommendations may not be backed by strong fundamentals. Therefore we advise readers to use their own discretion before investing in these recommendation.

COMPUTING GOOD GROWTH

NIIT Technologies
BSE Code: 532541
CMP: Rs 1,420.50 

NIIT Technologies a leading global IT solutions organisation servicing customer across the Americas, Europe, Asian and Australia. The company has reported a 19 per cent jump in consolidated revenue to Rs 1,109.3 crore and an 11.4 per cent rise in the net profit to Rs 113.6 crore over the same period last year. Cumulative order intake for the year is USD 748 million, up 16 per cent over the previous year. In Q4FY20, the order intake was USD 180 million that included three large deals. It reflects the continued deal signing momentum. Further, the firm recorded one of its best annual performances ever in FY 2020, which has come on the back of a similarly strong performance delivered in the preceding year. As per our sources, this stock could be a re-rating candidate and the targets on the upside are going to be quite attractive from the current levels. Hence, traders and investors can expect strong momentum in the stock. 

IN A STRONG POSITION 

Bharat Dynamics
BSE Code: 541143
CMP: Rs 223.25 

BDL is one of the technologically advanced leading suppliers of missiles and allied products to the Indian defence sector as well as India’s friendly countries. The company has received an order worth Rs 293.33 crore towards supply of MRSAM missile sections for Indian Air Force deliverables. The price movement in this stock in the recent past has been accompanied with very good volumes. The stock price is expected to see further upward movement. Traders with high risk appetite may add this stock to the portfolio. 

INSURED FOR SUCCESS

SBI Life Insurance
BSE Code: 540719
CMP: Rs 731.55 

The company reported a 16 per cent rise in its net profit at Rs 530.67 crore for the quarter ended March 2020. Its net premium during the quarter increased to Rs 11,862.98 crore from Rs 11,333.02 crore a year earlier. Further, the company continued to gain market share in FY 2020 through its top private competitors. Also, technically the stock is looking promising and is poised for a decent upward movement in the near term. Hence, traders can opt for this stock as momentum play. 

ON A HEALTH TRIP 

Dr. Lal Pathlabs
BSE Code: 539524
CMP: Rs 1,582.90

Dr. Lal PathLabs Limited is an international service provider of diagnostic and related healthcare tests. Based in Delhi, the company offers a broad range of tests on blood, urine and other human body viscera. It has been noticed that some market operators are reportedly becoming active on this counter due to which it is likely to witness a spurt in its price in the coming days. Risk-takers can go for this scrip and hope to make a quick buck. 

(Closing price as of May 06, 2020)

Rate this article:
No rating
Comments are only visible to subscribers.

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR